Nymox Announces Fexapotide Drug Symposium at AUA Annual Meeting San Francisco May 20
May 02, 2018 09:30 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., May 02, 2018 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that there will be a Symposium on the Company's lead drug Fexapotide...
Nymox Announces $16.25 Million Equity Financing With Qualified Long-Term Investors
April 12, 2018 09:45 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., April 12, 2018 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce today that the Company has successfully secured $16.25 million in...
New Online Commentary in UroToday on Fexapotide BPH Clinical Trial Results Publication in World Journal of Urology
April 10, 2018 10:00 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., April 10, 2018 (GLOBE NEWSWIRE) -- A new online published commentary about Nymox’s (NASDAQ:NYMX) Fexapotide 2018 clinical trial results publication in World Journal of...
Symposium and Panel Discussion on Nymox's Fexapotide To Be Held at American Urological Association Mid-Atlantic Section Annual Meeting on March 3
March 01, 2018 09:30 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., March 01, 2018 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report that a Symposium on Fexapotide Triflutate studies will be held at the...
Nymox Announces US NDA for Fexapotide for BPH
February 05, 2018 11:15 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today that the Company will submit a New Drug Application (NDA) for Fexapotide...
Fexapotide BPH Phase 3 Clinical Trial Results Published in World Journal of Urology
January 30, 2018 09:30 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., Jan. 30, 2018 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) reports today that the results of Phase 3 clinical studies of Fexapotide Triflutate...
Nymox Reports 5-Year Results From Prospective Randomized Controlled Prostate Cancer Study of Fexapotide Triflutate in 146 U.S. Men
January 22, 2018 11:30 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) reported today top-line 5-year results from Nymox's U.S. Study NX03-0040. Study NX03-0040...
Nymox Fexapotide Symposium and Panel Discussion at American Urological Association South Central Sectional Annual Meeting in Naples FL
November 27, 2017 11:00 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report on the Symposium which was held on Fexapotide Triflutate studies at the...
Nymox Fexapotide Symposium and Panel Discussion at American Urological Association North Central Sectional Annual Meeting in Scottsdale
November 16, 2017 11:10 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report on the Symposium which was held on Fexapotide Triflutate studies at the...
Symposium and Panel Discussion on Nymox's Fexapotide To Be Held at American Urological Association North Central Section Annual Meeting in Scottsdale AZ November 15
November 10, 2017 10:30 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., Nov. 10, 2017 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report that a Symposium on Fexapotide Triflutate studies will be held at the...